Background
==========

Progress in TB control is further hindered by the continued use of timeworn diagnostic methods. Although conventional drug sensitive test (DST) can provide definitive results and remains the gold standard method for tuberculosis detection, this testing method is extraordinarily time consuming and lead to many patients to go undiagnosed and untreated, allowing for continued spread of TB in the area. The delayed diagnosis may be bring about an incorrect or incomplete treatment. Defect of treatment is thought to be a driving forces behind the emergence of multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB), Moreover, DST is not conventionally used for spinal tuberculosis in most resource-poor hospitals in China because of biosafety concerns and inadequate infrastructure, which reveals key constraints for therapy of the disease. Therefore, the development of a rapid and accurate molecular detection of MDR-TB in clinical hospitals has become the focus of attention.

Recently, Nucleic acid amplification tests (NAAT) have become more common in the diagnosis of tuberculosis. Several commercial molecular test kits have been developed for the detection of gene mutations associated with MDR-TB ([@B2]; [@B3]; [@B5]; [@B13]; [@B17]; [@B22]). However, Resistance of many SLD is still not rapidly detectable. Moreover, most of these detection products specifically amplify the genetic material of the causative organisms to detectable levels through PCR technology, and are unable to detect a large number of gene mutations.

As an integrated system, gene chip, fixed with thousands of functionalized probes, can achieve accurate, and rapid analysis for MDR-TB samples. Based on the detection of Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR)-magnetic bead Tag Array platform, we developed the Tag Array chip, allowing sensitive and specific detection. Moreover, specimens of spinal and pulmonary tuberculosis were analyzed to verify the effect in a clinical application.

Materials and Methods {#s1}
=====================

Study Design and Specimens
--------------------------

Specific primer sequences are shown (**Supplementary Material [1](#SM1){ref-type="supplementary-material"}**).

In order to obtain sufficient clinical samples, we organized six other hospitals (including three TB specialist hospitals) to work together for clinical sample collection. The achieved specimens after decontamination were preserved in a −30°C freezer for later analysis by the Tag Array chip. In order to avoid bias, specimens were excluded if the patient already received anti-TB drug treatment for more than 2 weeks before the sample collection. Finally, there were 421 specimens (234 sputum samples and 187 spinal samples). The Tuberculosis Drug Resistance Mutation Database (TBDReaMDB) was used to access to RFP, INH, EMB, fluoroquinolone ketone, aminoglycoside and cyclic peptide (amikacin, KM and CPM and other common drug resistance genes, mutations and mutation coverage (**Table [1](#T1){ref-type="table"}**), covering a relatively wide selection of mutations.

###### 

Resistance gene loci and coverage.

  Drug                                                                     Drug resistance gene   Coverage rate(%)   Mutation site   Coverage rate(%)
  ------------------------------------------------------------------------ ---------------------- ------------------ --------------- ------------------
  Rifampin                                                                 rpoB                   84%                511             1%
                                                                                                                     513             
                                                                                                                     516             3%
                                                                                                                     522             1%
                                                                                                                     526             20%
                                                                                                                     531             55%
                                                                                                                     533             4%
  Isoniazid                                                                katG                   68%                315             51%
                                                                           inhA                                      -15             18%
                                                                           oa                                        −10             
                                                                                                                     −39             
  Streptomycin                                                             rpsL                   85%                43              72%
                                                                                                                     88              5%
                                                                           rrs                                       513             7%
                                                                                                                     516             1%
  Ethambutol                                                               embB                   57%                306             57%
  Fluoroquinolones                                                         gyrA                   92%                90              29%
                                                                                                                     94              57%
                                                                                                                     91              6%
  Aminoglycosides/ Cyclic peptides (Amikacin, kanamycin and Aspergillus)   rrs                    ---                1401            
                                                                                                                     1402            
                                                                                                                     1484            

Processing of Specimens and Mycobacteriology Analyses
-----------------------------------------------------

All clinical specimens were decontaminated using the N-acetyl-L-cysteine (NALC) −NaOH method (18) with a final NaOH concentration of 1%. After concentration by centrifugation (20 min at 3,000 × *g*), the sediment was re-suspended in 1.5 ml of 0.5 M phosphate buffer (pH 6.8) and inoculated for culture on both Lowenstein-Jensen (LJ) solid media and the BACTEC MGIT 960 (Becton-Dickinson, Sparks, MD, United States) system, and the sensitivity test for eight kinds of anti-TB drugs proceeded with a modified absolute concentration method, according to the rules for the bacteriological diagnosis of tuberculosis ([@B32]).

DNA Sequencing of Drug Resistance-Associated Genes
--------------------------------------------------

Genomic DNA was isolated from bacteria cultured on L-J medium. A bacteria loop was suspended in water (500 μl) and heated at 95°C for 15 min. The DNA used for amplification by PCR was obtained by heat shock extraction (1 min at 95°C and 1 min on ice, repeated five times). A volume of 5 μl was used in PCR with the oligonucleotide primers described below. To detect RFP resistance, the rpoB gene were amplified and sequenced using primers 5′-AGGCGATCACACCGCAGACGT-3′ and 5′- GCCGATCAGACCGATGTTGG −3′. For detection of SM resistance, the rpsL gene were amplified and sequenced using primers 5′-CTGGTCCGCAAGGGTCGTC-3′ and 5′-CCCTGCGTCCAGCGAACC-3′. To detected INH resistance, the katG and inhA were amplified and sequenced using, respectively, primers 5′-CTCTTCGTCAGCTCCCACTCG-3′, and 5′- GTCGGCGGTCACACTTTCG-3′ and primers 5′-GGGTTTGGCCCCTTCAGTG-3′, and 5′-GCCTCGCTGCCCAGAAAG-3′. To detect EMB resistance, the embB gene were amplified and sequenced using primers 5′-CGTGGTGATATTCGGCTTCCTG-3′ and 5′-TGCCGAACCAGCGGAAATAG-3′. For detection of FQs resistance, the QRDRs of gyrA were amplified and sequenced using primers 5′-AGCATCTCCATCGCCAACGG-3′ and 5′-ACCGCAGCCACGCCAAGTC-3′. To detected the second-line anti-TB drugs (AMK, CPM, and KM) resistance, the rrs gene (positions 1401 to 1484) were amplified and sequenced using, respectively, primers 5′-AGAACCCCTCACGGCCTACG-3′ and 5′-GCAACGCTGCGGTGAATACG-3′. After amplification, unincorporated nucleotides and residual primers were filtered and removed (**Supplementary Material [2](#SM2){ref-type="supplementary-material"}**).

Tag Array Chip Assays
---------------------

The chip design see **Tables [2](#T2){ref-type="table"}**, **[3](#T3){ref-type="table"}** and **Figure [1](#F1){ref-type="fig"}**. A visible colony was chosen, placed on the tube containing nucleic acid extraction buffer (100 μl: 5 mg/ml lysozyme, 2mg/ml Proteinase K, 1% Sodium dodecyl sulfate (SDS), potassium acetate, phenol/chloroform/isoamylol 25:24:1), oscillated for 5 min, then placed in a 95°C water bath for 5 min, and stored at −20°C. PCR fluorescence probe quantitatively analyzed the extracted nucleic acid. According to the concentration, samples were diluted or concentrated: the concentration of DNA were 1 × 10^2^ copies/μL (group 1), 1 × 10^3^ copies/μL (group 2), 1 × 10^4^ copies/μL (group 3), 1 × 105 copies/μL RFP (group 4), 5 × 105 copies/μL (group 5), 1 × 106 copies/μL (group 6). Each sample proceeded to eight tubes for PCR amplification. 25 μl amplification PCR reagents and 5 μl template DNA were added to each tube, in a total reaction volume of 30 μl for PCR amplification.

###### 

Microarray probe design.

  Probe species               Probe name   Probe meaning                                            Probe name   Probe meaning
  --------------------------- ------------ -------------------------------------------------------- ------------ -----------------------------------------
  Quality control probe       QC           SuFace chemical quality control probe                    BC           Blank control probe
                              PC           Hybrid positive control probe                            MC           The Magnetic bead quality control probe
                              gbTAG282     Quality control probe for *Mycobacterium tuberculosis*                
  Gene site detection probe   gbTAG197     gyrA90 Mutant probe                                      gbTAG235     oa-10 Mutant probe
                              gbTAG264     gyrA91 Mutant probe                                      gbTAG217     rrs1401 Mutant probe
                              gbTAG200     gyrA94 Mutant probe                                      gbTAG279     rrs1402 Mutant probe
                              gbTAG275     embB306 Mutant probe                                     gbTAG205     rrs1484 Mutant probe
                              gbTAG168     embB306 Mutant probe                                     gbTAG171     katG315 Mutant probe
                              gbTAG198     katG315 Mutant probe                                     gbTAG245     rpoB511 Mutant probe
                              gbTAG206     inhA-15 Mutant probe                                     gbTAG257     rpoB513 Mutant probe
                              gbTAG104     rpsL43 Mutant probe                                      gbTAG209     rpoB516 Mutant probe
                              gbTAG221     rpsL88 Mutant probe                                      gbTAG108     rpoB522 Mutant probe
                              gbTAG270     rrs513 Mutant probe                                      gbTAG277     rpoB526 Mutant probe
                              gbTAG301     rrs516 Mutant probe                                      gbTAG273     rpoB531 Mutant probe
                              gbTAG202     oa-39 Mutant probe                                       gbTAG260     rpoB533 Mutant probe

###### 

Microarray probe design description.

       1--3       4--6       7--9       10--12
  ---- ---------- ---------- ---------- ----------
  1    QC_HEX     BC         MC         EC
  2    gbTAG197   gbTAG270   gbTAG245   
  3    gbTAG264   gbTAG301   gbTAG257   
  4    gbTAG200   gbTAG202   gbTAG209   
  5    gbTAG275   gbTAG235              
  6    gbTAG168   gbTAG217   gbTAG108   
  7    gbTAG198   gbTAG279   gbTAG277   
  8    gbTAG206   gbTAG205   gbTAG273   gbTAG282
  9    gbTAG104   gbTAG171   gbTAG260   
  10   gbTAG221                         
  11   EC         MC         BC         QC_HEX

![Schematic diagram of experimental principle.](fmicb-09-02106-g001){#F1}

The eight PCR reactions of each sample were combined into two centrifuge tubes. The reaction conditions are shown in **Supplementary Materials [3](#SM3){ref-type="supplementary-material"}**. 40 μl of the prepared magnetic bead suspensions were added, and stood. The mixture was placed onto the magnetic frame, and adsorbed for 15 s. After added 60 μl 0.1 N NaOH, the tube was adsorbed for 15 s on the magnetic frame. With 40 μl hybridization buffer, the centrifuge tube adsorbed for 15 s again, next added to the hybrid buffer for hybridization. Each purified sample was added to two microarrays, and the hybrid reaction mixture was slowly injected through the sample-adding hole, until the chip was covered (about 15.5 μl). Then the sealed chip was placed inside to initiate the hybridization reaction (50°C, 1 h), and read the signal using a microarray chip scanner (LuxScan 10K-B). The detection time is 6--8 h.

Data Analysis
-------------

The chip test results were compared with previous sequencing results to evaluate the accuracy of gene detection. These results were also compared with bacterial culture and the results of the absolute concentration method for drug susceptibility testing. In cases of discrepant results, the medical history, clinical feature, and histopathological examination of patients were included in the final evaluation.

The specificity (The true negative rate: the probability of actual resistance was proved to be resistant by culture + DST), sensitivity (The true positive rate: The probability that the drug is actually non-resistant and is proved to be non-resistant by culture + DST), and the accuracy (the degree to which the observed value corresponds to the standard value) of the two generations of drug-resistant TB chips were evaluated.

This research was approved by the Ethics Committee of the First Affiliated Hospital of the Third Military Medical University, People's Liberation Army.

Results
=======

Phenotypic Drug Sensitivity of *Mycobacterium tuberculosis*
-----------------------------------------------------------

Spinal Tuberculosis: 67 aminoglycosides (AMK, CPM, KM) resistant strains, 44 EMB resistant strains, 112 SM resistant strains, 118 INH resistant strains, and 126 rifampicin resistant strains. Pulmonary Tuberculosis: 89 aminoglycosides (AMK, CPM, KM) resistant specimen, 72 ethambutol resistant specimen, 98 streptomycin resistant specimen, 103 isoniazid resistant specimen, and 124 rifampicin resistant specimen. The above gene loci were previously sequenced.

Comparison of Chip Scanning and Phenotypic Drug Results, and Analysis Sensitivity and Specificity
-------------------------------------------------------------------------------------------------

1\. Spinal Tuberculosis: Among 126 RFP resistant phenotype strains, 119 strains were identified to have rpoB gene mutations; in phenotypically sensitive strains, four were identified as having rpoB gene mutations. The mutation frequency of rpoB531 was 78 strains (60.93%), rpoB516 was 20 strains (15.63%), rpoB513 was nine strains (7.03%), rpoB511 was nine strains (7.03%), rpoB511 was six strains (4.69%), and 11 strains had multiple mutations in the rpoB gene. The sensitivity and specificity of rifampicin (RFP) were 94.40 and 92.86%. Of 118 strains that were INH resistant, 109 strains were detected as having phenotypic resistance; whereas, in sensitive strains, 13 strains were detected. The mutation frequency of KatG315 was 105 strains (86.07%), inhA −15 was 31 strains (25.41%), oxyR-ahpC was six strains (4.92%). There are 21 strains that shared KatG315 and inhA −15 mutations, but no oxyR-ahpC gene mutation was associated with other strains. The sensitivity and specificity of INH were 92.37 and 87.50%.

Among the 44 strains of EMB resistant phenotypes, there were 27 strain mutations in the embB306 site, and embB306 mutation was detected in six phenotypically sensitive strains. Mutations occurred in the gyrA gene in 81 strains of 102 strains of quinolone resistant strains; in sensitive strains, four strains had the gyrA gene mutation. Overall, the mutation rate from high to low for gyrA94 was 55 strains (64.71%), gyrA90 was 25 strains (29.42%), and gyrA91 was four strains (4.71%). In 112 strains of SM resistant strains phenotype, the chip detected 101 strains of resistant genes in mutation sites; at the same time, in sensitive strains, 12 strains exhibited mutations. The mutation frequency for rpsL 43 was 91 strains (80.53%), rpsL88 was 16 strains (14.16%), rrs513 was six strains (5.31%), and rrs516 was two strains (1.77%). The sensitivity and specificity of EMB. FQs and SM were 61.36%, 89.29%; 79.41%, 92.86%; 90.18%, 89.29%

2\. Pulmonary Tuberculosis: Among 124 rifampin resistant phenotype strains, 115 strains were identified to have rpoB gene mutations; in phenotypically sensitive strains, three were identified as having rpoB gene mutations. The mutation frequency of rpoB531 was 66.94%, rpoB516 was 18.18%, rpoB513 was 6.61%, rpoB511 was 4.13%, rpoB511 was 1.65%, rpoB511 was 2.48%, and 14 strains had multiple mutations in the rpoB gene. Of 103 isoniazid phenotypic resistant strains, 94 strains were detected as having gene mutation; in phenotypic sensitive strains, six strains were detected. The mutation frequency of KatG315 was 80.20%, inhA −15 was 12.87%, oxyR-ahpC was 6.93%. There are 24 strains that shared KatG315 and inhA −15 mutations, but no oxyR-ahpC gene mutation was associated with other strains.

Among the 72 strains of ethambutol resistant phenotypes, there were 39 strain mutations in the embB306 site, and five embB306 mutation was detected in phenotypically sensitive strains. Mutations occurred in the gyrA gene in 101 strains of quinolone resistant strains; in sensitive strains, three strains had the gyrA gene mutation. Overall, the mutation rate from high to low for gyrA94 was 66.36%, gyrA90 was 26.17%, and gyrA91 was 7.48%. In streptomycin resistant strains phenotype, the chip detected 85 strains of resistant genes in mutation sites; in sensitive strains, seven strains exhibited mutations. The mutation frequency for rpsL 43 was 86.92%, rpsL88 was 9.35%, rrs513 was 1.87%, and rrs516 was 1.87%. The sensitivity and specificity respectively were RFP: 92.74%; 93.75%; INH: 91.26%; 87.50%; EMB: 54.17%; 89.58%; FQS: 84.87%; 93.75%; SM: 86.73%; 85.42%.

Because AMK, CPM, KM possess cross resistance, the results were combined when analyzed (clinical isolates, as long as there was resistance to one or more drug, named resistant strains). Spinal Tuberculosis: In 67 phenotypically resistant strains, 52 strains had mutations; of the sensitive strains, 11 strains had rrs1401 gene mutations. The frequency of mutation for rrs1401 was 62 strains (98.41%), rrs1484 was one strain (1.59%), and rrs1402 was no strains (0.00%). Pulmonary Tuberculosis: In 89 phenotypically resistant strains, 72 strains had mutations; of the sensitive strains, four strains had rrs1401 gene mutations. The frequency of mutation for rrs1401 was 96.05%, rrs1484 was 3.95%, and rrs1402 was 0.00%. The sensitivity and specificity of SLD in spinal and pulmonary tuberculosis were 77.61%, 83.93%, 80.9%, 91.67%. Detailed results are illustrated in **Tables [4](#T4){ref-type="table"}**, **[5](#T5){ref-type="table"}**. Hybridization results are shown in **Figures [2](#F2){ref-type="fig"}**, **[3](#F3){ref-type="fig"}**.

###### 

Sensitivity, specificity and consistency of chip detection and phenotypic resistance (Spinal tuberculosis strains).

  Anti-tuberculosis drugs   Sensitivity (%)         Specificity (%)         Accuracy (%)
  ------------------------- ----------------------- ----------------------- -----------------------
  RMP                       94.40\[91.06--97.74\]   92.86\[89.12--96.60\]   93.96\[90.46--97.42\]
  INH                       92.37\[88.43--96.31\]   87.50\[82.6--92.41\]    90.80\[86.51--95.09\]
  EMB                       61.36\[51.82--70.90\]   89.29\[83.23--95.35\]   77.00\[68.75--85.25\]
  SM                        90.18\[85.68--94.68\]   89.29\[84.61--93.97\]   89.88\[85.32--94.44\]
  fQs                       79.41\[73.10--85.72\]   92.86\[88.84--96.88\]   84.18\[78.49--89.87\]
  SLID                      77.61\[75.28--79.94\]   83.93\[77.44--90.42\]   80.49\[73.49--87.49\]

###### 

Sensitivity, specificity and consistency of chip detection and phenotypic resistance (Pulmonary tuberculosis strains).

  Anti-tuberculosis drugs   Sensitivity (%)         Specificity (%)         Accuracy (%)
  ------------------------- ----------------------- ----------------------- -----------------------
  RMP                       92.74\[88.86--96.62\]   93.75\[90.13--97.37\]   93.02\[89.21--96.83\]
  INH                       91.26\[86.76--95.76\]   87.50\[84.81--90.19\]   90.07\[88.34--93.06\]
  EMB                       54.17\[45.26--63.08\]   89.58\[84.11--95.05\]   68.33\[60.01--76.65\]
  SM                        86.73\[81.23--92.23\]   85.42\[79.70--91.14\]   86.30\[80.72--91.88\]
  fQs                       84.87\[79.44--90.30\]   93.75\[90.08--97.42\]   87.43\[82.40--92.46\]
  SLID                      80.90\[74.32--87.48\]   91.67\[87.04--96.30\]   84.67\[78.64--90.7\]

The sensitivity and specificity of gene chip was based on the improved absolute concentration of drug sensitivity method. \[\]: 95% CI.

![Test results of the experiment--Part 1.](fmicb-09-02106-g002){#F2}

![Test results of the experiment--Part 2.](fmicb-09-02106-g003){#F3}

Discussion
==========

Today, TB is still the main reason of leading death in the worldwide. Strengthening laboratory diagnostic is an important part of controlling TB epidemic. However, conventional DST for M. tuberculosis still relies on culture of the bacilli and requires a minimum of several weeks, therefore, ineffective anti-TB regimens may cause acquired drug resistance and local recurrence during this period ([@B25]). Moreover, DST for TB spondylitis is not performed routinely in most resource-poor hospitals in China because of the biosafety concerns and inadequate infrastructure, which present a major hindrance for the treatment of the disease. Therefore, rapid, accurate detection and early diagnosis is necessary for the successful management of MDR-TB in China ([@B8]).

In addition to genotype, MTBDRsl can simultaneously detect resistance to FQS, amikacin, kanamycin (KM), capreomycin (CPM), EMB. Other products detect only RIF and or INH resistance. Resistance in many second-line drugs is still not rapidly detectable. A Tag Array gene chip takes around four to 6 h to detect TB drug resistance. It is important for doctors to rapidly diagnose tuberculosis early and process individualized chemotherapy.

Tag Array TB chip, can synchronously detect the total 38 mutants of 22 mutant sites, and can be used for detecting resistance to RFP, INH, EMB, SM, AMK/CPM/KM, FQS, etc. Furthermore, in an emergency or extreme cases, the visual chip can be estimated result by eyes, which reduces experimental conditions.

Some studies have reported the rpoB gene mutation rate to be 96-100% in RFP resistant *Mycobacterium tuberculosis* ([@B12]; [@B28]). A high frequency of mutation sites occurred in rpoB531 and rpoB526, which was consistent with experimental results ([@B9]). This study selected the rpoB gene to represent RFP resistance detection, and the sensitivity was 94.40% (spine) and 92.74% (pulmonary), whereas the specificity was 92.86% (spine) and 93.75% (pulmonary). The result of the detection analysis was in the same levels of what has been reported from other commercial NAATs ([@B12]; [@B9]; [@B28]).

Mutations in the KatG gene confer high level INH resistance. S315T genetic mutations mainly caused decreased INH substrate affinity at the expense of only modest reduction in overall catalase activity. At the same time, the mutations in the inhA (associated with low-level INH resistance and cross-resistance to ethionamide) and ahpC genes are closely related to INH resistance ([@B31]; [@B10]). In the United States, the sensitivity of detecting mutations in INH resistance is close to 100% ([@B4]; [@B18]; [@B20]), but some study observed that the rate of INH resistance are related to location, so affecting the sensitivity of related gene mutation detection methods ([@B1]; [@B21]; [@B33]). Linger et al. detected MDR-TB in pulmonary tuberculosis using simplified microarray system, they observed that the sensitivity for INH was 90.0%, and the specificity was 98.2% ([@B19]). [@B8] reported the detection efficiency of GenoType MTBDRplus in bone and joint tuberculosis, the sensitivity was 85.71%, and the specificity was 100% for INH resistance. In our research, the chip detection sensitivity was 92.37% (spine) and 91.26% (pulmonary), the specificity was 87.50% (spine) and 87.50% (pulmonary).

Ethambutol is combined with INH, rifampicin and pyrazinamide in standard chemotherapy, and the resistance rate is lower than SM ([@B4]). Previous studies have shown that the embB gene, especially the codon embB306 mutation, is the main mechanism of EMB resistance, and also includes the 319, 354, 406 mutation sites ([@B29]). Recently, there have been reports of false positive and false negative results in the molecular diagnosis of tuberculosis drug resistance. This was related to the coverage of resistant sites, undiscovered resistance sites and mechanisms of drug resistance ([@B24]; [@B16]). However, some reports showed that only 28-68% of EMB resistant tuberculosis contains the embB306 mutation ([@B23]; [@B10]), and the sensitivity to molecular diagnostic testing of EMB resistance was 60-80%, and the specificity was 93-100% ([@B26]). Our chip detection results were consistent with previously reported data, showing high specificity, but poor sensitivity. According to the data analysis, we believe that the possibility of phenotypic EMB resistance is very large when the chip gives a positive result; but that negative chip results have little reference value and may also occur with phenotypic resistance.

Levofloxacin, moxifloxacin, and gatifloxacin are commonly used anti-tuberculosis second-line drugs. They target the DNA gyrase, and is coded for by 2 genes, gyr A and B. When mutations occur within the gyrA region, which determines resistance (most commonly gyrA94 and gyrA90 mutations), it will result in different levels of quinolone resistance ([@B11]). Some studies, using linear probe analysis, pyrosequencing, or Sanger sequencing detected quinolone resistance and compared it with phenotypic resistance. The results showed that sensitivity was 80% and specificity was 100% ([@B24]; [@B20]). In our research, the sensitivity was 79.41% (spine) and 84.87% (pulmonary), the specificity was 92.86% (spine) and 93.75% (pulmonary). The results were consistent with previously reported data, showing high specificity, but poor sensitivity.

In China, SM resistance mutations are very high, mainly because SM has been applied as the first-line anti tuberculosis drug there for many years. The resistance variable sites are located in rpsL43, rpsL88, rrs531, rrs516. The TBDReaMDB database shows that these four mutation sites cover 85% SM resistant tuberculosis, including rpsL43 (72%), rpsL88 (5%), rrs531 (7%), rrs516 (1%) ([@B30]). The sensitivity of our chip was 90.18% (spine) and 86.73% (pulmonary), specificity was 89.29% (spine) and 85.42% (pulmonary), yet this still has a high detection efficiency.

Amikacin and CPM cross resistance is caused by mutations in the rrs1400 region, and mainly appear in the 1401, 1402, 1484 sites ([@B15]; [@B7]; [@B27]). RrsA1401G mutations can lead to KM (60%), AMK and Aspergillus (75%) resistance; therefore, this site mutation should be used as a drug resistance marker of the three drugs ([@B6]). It has been reported that the rrsA1401G mutation was found to be resistant to KM (100%), AMK (100%) and CPM (63%). In addition, rrs1402 and 1484 mutations also occurred in a similar cross resistance situation ([@B14]). Furthermore, the sequence was unable to achieve an accurate assessment of the resistance of KAN, AMK and CAP respectively. A high rate of incidence of cross resistance in the rrs1400 region was also undeterminable. if a common site mutation is discovered, the three drugs should be excluded from chemotherapy. In this research, we judged drug resistance as phenotypic resistance including one antibiotic, which improved the effectiveness of early chemotherapy and avoided ineffective chemotherapy. The literature reported that for molecular detection of the rrs1400 mutation, compared with phenotypic detection, the sensitivity was 60.4%, and specificity was 100%. For GenoType MTBDRsl, the sensitivity was 86.4%, and the specificity was 90.1% ([@B6]). Our research found that chip sensitivity was 77.61% (spine) and 80.9% (pulmonary), and specificity was 83.93% (spine) and 91.67% (pulmonary). The sensitivity was lower than the GenoType MTBDRsl assay, which may be related to no detection in the eis promoter region.

Conclusion
==========

The detection condition of this chip is not high, allowing to be used in any lab that uses the traditional method, hence, it is easy to popularize in the developing countries. Compared with other currently available detected methods, this method is less cost and time-consuming, more detected drugs and genetic site than both Bactec 960 TB and other molecule detected methods, and correlates very well as predictor of resistance. The EMB resistance gene has low sensitivity, and it is therefore easy to misdiagnose; however, its specificity is high, which provides an important reference value. We believe this gene chip is promising for future testing for reduces difficulties of the traditional detected methods, while improving accurate testing of MDR-TB or XDR-TB.
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